Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets

Protalix Biotherapeutics ((PLX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Protalix Biotherapeutics’ latest earnings call struck an upbeat tone, powered by a hefty milestone payment that flipped the company to profitability and reinforced its cash position. Management balanced this optimism with a candid acknowledgment of softer product sales, higher R&D spending, and some uncertainty around the pace of commercial uptake and clinical enrollment.

Milestone Payment and Strong Cash Position

Protalix received a $25 million milestone from partner Chiesi after European approval of Elfabrio’s every‑four‑weeks dosing regimen. That payment helped the company end Q1 2026 with $51 million in cash, cash equivalents, and short‑term deposits, with no debt or warrants, giving it meaningful financial flexibility.

Reaffirmed 2026 Revenue Guidance

Despite quarterly volatility, management reaffirmed full‑year 2026 revenue guidance of $78 million to $83 million, including the $25 million milestone. Within that range, Protalix still expects $33 million to $35 million in Elfabrio revenue excluding milestones and $20 million to $23 million from Elelyso, signaling confidence in the underlying business.

Quarterly Profitability Driven by Milestone

The milestone transformed Q1 results, with Protalix reporting net income of $18.3 million, or $0.23 per share, versus a $3.6 million loss in the prior‑year quarter. That $21.9 million swing was largely tied to the payment from Chiesi, highlighting both the value of the partnership and the non‑recurring nature of this quarter’s profit.

Commercial Momentum and Opportunity for Elfabrio

European Commission approval of Elfabrio’s once‑every‑four‑weeks regimen is expected to ease treatment burden and support differentiation in the competitive Fabry disease market. Management believes Elfabrio could ultimately capture 15% to 20% of a global Fabry market projected to approach $3.2 billion by 2031, underscoring its long‑term commercial potential.

Progress on PRX‑115 Clinical Pipeline

The company highlighted PRX‑115 as a top clinical priority, with the Phase II RELEASE trial now enrolling patients. Protalix increased R&D spending to advance this program and reiterated expectations for top‑line data in the second half of 2027, positioning PRX‑115 as a key future growth driver if the study delivers.

Lower Cost of Revenues Supporting Margins

Cost of revenues fell sharply to $4.1 million in Q1 2026 from $8.2 million a year earlier, a roughly 50% reduction. This drop, driven partly by lower volume to certain partners, translated into improved gross margins in the quarter and helped amplify the earnings impact of the milestone payment.

Decline in Product Sales Raises Questions

Against these positives, revenues from selling goods slipped to $7.4 million in Q1 2026 from $10 million a year ago, a 26% decline. Management attributed the shortfall mainly to lower Elelyso purchases by Pfizer and Fiocruz tied to timing and inventory dynamics, but investors will watch closely to see if volumes normalize.

Higher R&D Spending to Fuel Growth

R&D expenses rose to $5.4 million from $3.5 million, a 54% increase year over year, reflecting preparations for and initiation of the PRX‑115 Phase II study. While this lifts near‑term cash burn, it also underscores Protalix’s willingness to invest in its pipeline to sustain longer‑term value creation.

Uncertain Timing for Elfabrio Uptake

Management cautioned that the revenue boost from Elfabrio’s new regimen will depend on country‑by‑country reimbursement progress by Chiesi across Europe and other regions. As a result, the company expects the most meaningful impact to show up in the second half of 2026, leaving some near‑term revenue timing uncertainty.

Limited Visibility on PRX‑115 Enrollment Pace

While the PRX‑115 RELEASE study is enrolling, management did not provide granular detail on recruitment metrics, beyond restating long‑term targets. This leaves some uncertainty around the ability to complete enrollment by the end of 2026 and deliver top‑line data in the second half of 2027 as planned.

Forward‑Looking Guidance and Outlook

Protalix reaffirmed 2026 revenue guidance of $78 million to $83 million, anchored by Elfabrio and Elelyso plus the Chiesi milestone, after reporting Q1 revenue of $33.8 million including the payment. Management expects Elfabrio’s uptake, supported by Chiesi, to accelerate in the back half of 2026, while targeting 15% to 20% Fabry market share and completion of PRX‑115 enrollment by year‑end 2026, with data in H2 2027.

Protalix’s earnings call painted the picture of a company using partnership milestones and a strengthened balance sheet to fund an ambitious growth plan. While softer product sales, higher R&D outlays, and execution risks around Elfabrio uptake and PRX‑115 enrollment bear monitoring, management’s reaffirmed guidance and clear strategic focus left an overall positive impression for investors tracking the story.